Orna Therapeutics, a biotechnology company dedicated to engineering immune cells in vivo to treat oncology and autoimmune diseases, announced the appointment of Joseph Bolen, Ph.D., as...
Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA®), announced its acquisition of...
Orna Therapeutics, a biotechnology company pioneering a new class of fully engineered circular RNA therapies (oRNA), announced the initial closing of its $221 million...
